{"id":4413,"date":"2019-03-26T03:03:58","date_gmt":"2019-03-26T03:03:58","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4413"},"modified":"2020-11-03T20:48:56","modified_gmt":"2020-11-03T20:48:56","slug":"%e8%be%be%e5%b8%83%e6%8b%89%e9%9d%9e%e5%b0%bc%e5%92%8c%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e5%9c%a8%e6%b2%bb%e7%96%97%e6%90%ba%e5%b8%a6braf-v600%e7%aa%81%e5%8f%98%e7%9a%84%e5%9f%83%e5%b0%94%e5%be%b7","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/zh\/study_trials\/dabrafenib-and-trametinib-in-treating-patients-with-erdheim-chester-disease-with-braf-v600-mutations\/","title":{"rendered":"\u8fbe\u5e03\u62c9\u975e\u5c3c\u548c\u7279\u62c9\u7f8e\u66ff\u5c3c\u5728\u6cbb\u7597\u643a\u5e26BRAF V600\u7a81\u53d8\u7684\u57c3\u5c14\u5fb7\u6d77\u59c6-\u5207\u65af\u7279\u75c5\u60a3\u8005\u4e2d\u7684\u5e94\u7528"},"content":{"rendered":"<p><strong>\u7814\u7a76\u76ee\u7684\uff1a&nbsp; <\/strong>\u8fd9\u9879II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u65e8\u5728\u8bc4\u4f30\u8fbe\u62c9\u975e\u5c3c\u548c\u66f2\u7f8e\u66ff\u5c3c\u8054\u5408\u6cbb\u7597\u643a\u5e26BRAF V600\u57fa\u56e0\u7a81\u53d8\u7684\u57c3\u5c14\u5fb7\u6d77\u59c6-\u5207\u65af\u7279\u75c5\u60a3\u8005\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002.<br \/>\n<strong>\u8d5e\u52a9\u5546\uff1a<\/strong>&nbsp; \u7f8e\u56fd\u56fd\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09<br \/>\n<strong>\u8bd5\u7528\u7248\u8054\u7cfb\u65b9\u5f0f\uff1a<\/strong>&nbsp; \u7814\u7a76\u534f\u8c03\u5458\uff1a\u963f\u5df4\u00b7\u963f\u8fbe\u7279\u5973\u58eb\uff0caadat@mdanderson.org\uff1b\u6216\u9996\u5e2d\u7814\u7a76\u5458\u83f2\u5229\u666e\u00b7\u626c\u5e93\uff0c713-563-1930\uff0cFJanku@mdanderson.org\u3002.<br \/>\n<strong>\u8981\u6c42\u60a3\u8005\u53c2\u4e0e\uff1a<\/strong>&nbsp; \u5e74\u9f84\u572818\u5c81\u53ca\u4ee5\u4e0a\u3001\u643a\u5e26BRAF V600\u7a81\u53d8\u4e14\u6b64\u524d\u672a\u63a5\u53d7\u8fc7BRAF\u6216MEK\u6291\u5236\u5242\u6cbb\u7597\u7684ECD\u60a3\u8005\u3002.<br \/>\n<strong>\u5df2\u77e5\u53c2\u4e0e\u8be5\u8bd5\u9a8c\u5e76\u63a5\u6536ECD\u60a3\u8005\u7684\u4e2d\u5fc3\uff1a<\/strong>&nbsp; MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\uff0c\u5fb7\u514b\u8428\u65af\u5dde\u4f11\u65af\u987f\u5e02<br \/>\n<strong>ClinicalTrials.gov \u6807\u8bc6\u7b26\uff1a<\/strong>&nbsp; NCT03794297<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective:&nbsp; This phase II trial investigates the efficacy and safety of dabrafenib and trametinib treatment in patients with Erdheim Chester disease that have BRAF V600 gene mutations. Sponsor:&nbsp; National [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[32],"class_list":["post-4413","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-drug-trial"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/zh\/wp-json\/wp\/v2\/study_trials\/4413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/zh\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/zh\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/zh\/wp-json\/wp\/v2\/media?parent=4413"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/zh\/wp-json\/wp\/v2\/study_trials_cat?post=4413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}